| West African Resources Limited (WAF) ORDINARY FULLY PAID |
Materials |
$3,191 |
WAF 10-year gold production to average 533,000 oz per annum
|
31 Mar 2026 8:22AM |
$3.050 |
$2.790 |
fallen by
8.52%
|
|
WAF - Price-sensitive ASX Announcement
Full Release
Key Points
- WAF targets 533,000 oz annual gold production from 2026 to 2035.
- Production to peak at 596,000 oz in 2030.
- Sanbrado mine plan extended to 2036; Kiaka reduced to 2041.
- Extensive drilling programs to convert Inferred Mineral Resources.
- Sanbrado to average 250,000 oz annually; Kiaka to average 270,000 oz.
- Secondary crushing to increase throughput at Sanbrado and Kiaka.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dyno Nobel Limited (DNL) ORDINARY FULLY PAID |
Materials |
$6,678 |
Update - Notification of buy-back - DNL
|
31 Mar 2026 8:22AM |
$3.110 |
$3.810 |
risen by
22.51%
|
|
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$5,260 |
Update - Notification of buy-back - WOR
|
31 Mar 2026 8:22AM |
$11.270 |
$10.780 |
fallen by
4.35%
|
|
| Reliance Worldwide Corporation Limited (RWC) ORDINARY FULLY PAID |
Industrials |
$2,872 |
Update - Notification of buy-back - RWC
|
31 Mar 2026 8:22AM |
$2.990 |
$3.840 |
risen by
28.43%
|
|
| Whitehaven Coal Limited (WHC) ORDINARY FULLY PAID |
Energy |
$5,847 |
Update - Notification of buy-back - WHC
|
31 Mar 2026 8:22AM |
$9.840 |
$7.110 |
fallen by
27.74%
|
|
| Percheron Therapeutics Limited (PER) ORDINARY FULLY PAID |
Health Care |
$5 |
New HMBD-002 Preclinical Data to be Presented at ASCO
|
31 Mar 2026 8:22AM |
$0.006 |
$0.004 |
fallen by
41.67%
|
|
| SiteMinder Limited (SDR) ORDINARY FULLY PAID |
Information Technology |
$1,115 |
Appendix 3Y - J Macdonald
|
31 Mar 2026 8:22AM |
$2.710 |
$3.940 |
risen by
45.39%
|
|
| Boom Logistics Limited (BOL) ORDINARY FULLY PAID |
Industrials |
$85 |
Update - Notification of buy-back - BOL
|
31 Mar 2026 8:22AM |
$1.670 |
$2.290 |
risen by
37.13%
|
|
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$59,371 |
Update - Notification of buy-back - CSL
|
31 Mar 2026 8:22AM |
$140.820 |
$123.970 |
fallen by
11.97%
|
|
| Bayan Mining and Minerals Limited (BMM) ORDINARY FULLY PAID |
Materials |
$8 |
Bayan joins U.S. Defense Industrial Base Consortium
|
31 Mar 2026 8:22AM |
$0.070 |
$0.058 |
fallen by
17.14%
|
|
BMM - Price-sensitive ASX Announcement
Full Release
Key Points
- Bayan Mining and Minerals Limited joins U.S. Defense Industrial Base Consortium.
- Membership provides access to U.S. Department of War programs and non-dilutive funding.
- Bayan's Yttrium Upgrade patent supports U.S. critical mineral supply chains.
- DIBC membership aligns with U.S. efforts to secure domestic rare earth element supplies.
- Bayan enhances its profile and potential contributions to the U.S. defense ecosystem.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$102 |
Paradigm Achieves 50% Patient Dosing in Phase 3
|
31 Mar 2026 8:22AM |
$0.260 |
$0.175 |
fallen by
32.69%
|
|
PAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Paradigm has achieved 50% patient enrolment in the global Phase 3 PARA_OA_012 trial.
- The trial evaluates injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis.
- Interim analysis results are expected in August 2026.
- The Phase 3 study design aligns with the earlier successful PARA_OA_008 trial.
- Improvements in trial methodology include real-time pain assessments and reduced placebo response.
- Paradigm aims to address both symptoms and underlying disease mechanisms of osteoarthritis.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Critical Resources Limited (CRR) ORDINARY FULLY PAID |
Materials |
$26 |
High-Grade Tungsten up to 42.6% WO3 as NZ Fieldwork Commence
|
31 Mar 2026 8:22AM |
$0.007 |
$0.008 |
risen by
14.29%
|
|
CRR - Price-sensitive ASX Announcement
Full Release
Key Points
- Fieldwork targets gold and tungsten in Otago and Reefton regions.
- Croesus project reports tungsten grades up to 42.6% WO3.
- Mineralisation corridor extends over 5 km at Croesus.
- Lammerlaw project focuses on structural gold systems.
- Projects align with New Zealand's pro-investment reforms.
- Tungsten prices increased due to supply concerns.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Capral Limited (CAA) ORDINARY FULLY PAID |
Materials |
$175 |
Update - Notification of buy-back - CAA
|
31 Mar 2026 8:22AM |
$11.320 |
$11.010 |
fallen by
2.74%
|
|
| REA Group Ltd (REA) ORDINARY FULLY PAID |
Communication Services |
$19,273 |
Update - Notification of buy-back - REA
|
31 Mar 2026 8:22AM |
$151.000 |
$147.280 |
fallen by
2.46%
|
|
| PolarX Limited (PXX) ORDINARY FULLY PAID |
Materials |
$41 |
Strong silver assays from Ridgeline prospect at Humboldt
|
31 Mar 2026 8:21AM |
$0.016 |
$0.015 |
fallen by
6.25%
|
|
PXX - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong silver assays reported from Ridgeline prospect.
- Silver assays envelop the entire drill program with notable gold assays also present.
- Mineralisation extends over an 800-meter strike length and remains open.
- Located near substantial North American gold and silver mines.
- Plans for a major follow-up drilling program to explore further mineralisation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kogan.com Ltd (KGN) ORDINARY FULLY PAID |
Consumer Discretionary |
$422 |
Update - Notification of buy-back - KGN
|
31 Mar 2026 8:21AM |
$3.420 |
$4.450 |
risen by
30.12%
|
|
| Infini Resources Limited (I88) ORDINARY FULLY PAID |
Materials |
$14 |
Reynolds & Reitenbach Lake Maiden Drill Targets Finalised
|
31 Mar 2026 8:21AM |
$0.130 |
$0.125 |
fallen by
3.85%
|
|
I88 - Price-sensitive ASX Announcement
Full Release
Key Points
- Maiden diamond drilling program to test uranium targets at Reynolds & Reitenbach Lake.
- Program scheduled for mid-April 2026 with a minimum of 2,500m of drilling.
- High-grade uranium mineralization discovered at Titus Prospect.
- Drilling focuses on EM conductors, magnetic features, and uranium geochemical anomalies.
- Integration of datasets from 2025 exploration programs.
- Projects located on the eastern margin of the Athabasca Basin.
- Potential for basement-hosted uranium mineralization similar to Eagle Point.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Battery Age Minerals Ltd (BM8) ORDINARY FULLY PAID |
Materials |
$11 |
BM8 Expands USA Germanium-Gallium Project Landholding by 40%
|
31 Mar 2026 8:21AM |
$0.057 |
$0.049 |
fallen by
14.04%
|
|
BM8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Battery Age Minerals Ltd (ASX: BM8) expands US landholding by acquiring 51 additional claims.
- The Apex Project is now 40% larger, totaling 186 claims and approximately 3,728 acres.
- The project is located in the Beaver Dam Mountains, Utah, USA.
- Apex is near a high-grade germanium-gallium operation, important for semiconductors and satellite technology.
- The company integrates remote sensing technology to enhance exploration efforts.
- Battery Age focuses on critical minerals exploration and supply chain development in the US and EU.
- The acquisition aims to secure ground adjacent to the historic Apex Mine.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MetalsGrove Mining Ltd (MGA) ORDINARY FULLY PAID |
Materials |
$15 |
Up to 583 ppb Gold in Soils at Fifty-Five Prospect, Zuenoula
|
31 Mar 2026 8:21AM |
$0.100 |
$0.096 |
fallen by
4%
|
|
MGA - Price-sensitive ASX Announcement
Full Release
Key Points
- Seven gold prospects defined by soil sampling at Zuénoula, including Fifty-Five Prospect with a peak 583 ppb Au anomaly.
- Fifty-Five Prospect upgraded to top-priority target within a 3.3 km-long anomalous corridor.
- Central Prospect confirmed with a 148 ppb Au anomaly within a broader zone.
- Additional prospects identified: Eastern, Rouge, Konezra, and South-West.
- Infill and extensional sampling programs planned, supported by regolith mapping and LiDAR data.
- High-resolution LiDAR surveys assist in mapping structural features and artisanal activities.
- MetalsGrove is earning up to 80% interest in Zuénoula PR-750.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Technology One Limited (TNE) ORDINARY FULLY PAID |
Information Technology |
$10,112 |
Becoming a substantial holder
|
31 Mar 2026 8:21AM |
$26.470 |
$30.890 |
risen by
16.70%
|
|
| FMR Resources Limited (FMR) ORDINARY FULLY PAID |
Communication Services |
$23 |
Mineralised Stockwork Breccia and Porphyry at Target L
|
31 Mar 2026 8:21AM |
$0.275 |
$0.360 |
risen by
30.91%
|
|
FMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Drillhole 26LHDD073 completed at Target L to a depth of 1,068 meters.
- Broad zones of mineralised stockwork breccia and porphyry identified.
- Visible copper and molybdenite sulphides observed.
- Phase I drilling exceeded 5,000 meters, revealing mineralised systems.
- Future exploration will target the core of the Southern Porphyry system.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Patrys Limited (PAB) ORDINARY FULLY PAID |
Health Care |
$26 |
Investor Presentation - Broker Meets Biotech
|
31 Mar 2026 8:21AM |
$0.028 |
$0.038 |
risen by
35.71%
|
|
PAB - Price-sensitive ASX Announcement
Full Release
Key Points
- Patrys Limited focuses on the development of a proprietary injectable formulation of quetiapine for ICU settings.
- The company has a de-risked development pathway with a 3–5 year timeline and lower costs compared to traditional biotech approaches.
- Patrys leverages existing extensive clinical data of quetiapine to reduce regulatory and technical risks.
- The injectable formulation is expected to have immediate onset and is suitable for ICU, palliative, and aged care settings.
- The estimated serviceable addressable market for the delirium treatment is over US$2 billion annually.
- Patrys plans to use the FDA 505(b)(2) regulatory pathway for accelerated development.
- Key development milestones include ethics approval for Phase 1A in Q2 2026 and IND submission by Q4 2027.
- The company has a market capitalization of $15M with plans to partner or license the product.
- The board of directors comprises experts in ASX governance, biotech commercialization, and clinical trial operations.
- Injectable quetiapine aims to address the unmet need in delirium treatment with a faster control of symptoms and reduced hospital stay costs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| FSA Group Limited (FSA) ORDINARY FULLY PAID |
Financials |
$163 |
Update - Notification of buy-back - FSA
|
31 Mar 2026 8:21AM |
$1.150 |
$1.300 |
risen by
13.04%
|
|
| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$25,659 |
Update - Notification of buy-back - BXB
|
31 Mar 2026 8:21AM |
$22.460 |
$19.210 |
fallen by
14.47%
|
|
| Fleetwood Limited (FWD) ORDINARY FULLY PAID |
Consumer Discretionary |
$172 |
Update - Notification of buy-back - FWD
|
31 Mar 2026 8:20AM |
$1.680 |
$1.910 |
risen by
13.69%
|
|